Home >
Law >
Medical Law >
Regulation of Genome Editing in Human iPS Cells: A Comparative Legal Analysis of National Regulatory Frameworks for iPSC-based Cell/Gene Therapies

Regulation of Genome Editing in Human iPS Cells: A Comparative Legal Analysis of National Regulatory Frameworks for iPSC-based Cell/Gene Therapies

Author: Hans-Georg Dederer; Gregor Frenken
Publisher: Springer-Verlag
ISBN: 9783030930226

Published In: May 2022
Format: Hardback
Jurisdiction: Switzerland ? Disclaimer:
Countri(es) stated herein are used as reference only
Paperback Edition ISBN: 9783030930257

RM1,005.41

Download Order Form

Add to Wishlist
| Add to Compare

Description
Contents

Details

The book provides a concise overview of currently applicable regulatory frameworks of states which are among the world leaders in research and development (R&D) of cell and gene therapies.

Developments in genome editing are expected to lead to new possibilities for the treatment of hereditary diseases in humans. The treatment of such often severe but hitherto uncurable diseases can be based on genome-edited induced pluripotent stem cells (iPS cells). Such treatments constitute combined cell/gene therapies. These therapies need to be governed by a regulatory framework which ensures quality, safety, and efficacy of the relevant therapeutic products. On the other hand, such regulations may retard product approval and impede R&D. Accordingly, national regulations for therapies based on genome-edited iPS cells are an important and, as the case may be, decisive factor for both researchers and industry regarding their decision where to locate their R&D activities. Therefore, regulatory frameworks impact significantly on the competitiveness of states and their economies.

This is why a comparative analysis of laws and regulations of different countries matters. Such a comparative legal analysis provides an important insight into regulatory concepts which, in turn, may inspire adjustments of, or amendments to, domestic legal regimes. For this purpose, experts present country reports on France, Germany, Japan, South Korea, Switzerland, and the USA. The reports on France and Germany also refer to the parameters and implications arising from pertinent EU law. This contributed volume is aimed at researchers, but also at, e.g., legal scholars, lawmakers, regulators, and political decision makers.

Introduction

Biological Aspects of Genome Editing in iPS Cells

Ethical Aspects in the Context of Genome Editing

Regulation of Genome Editing in iPS Cells: Germany

Regulation of Genome Editing in iPS Cells: France

Regulation of Genome Editing in iPS Cells: Switzerland

Regulation of Genome Editing in iPS Cells: United States

Regulation of Genome Editing in iPS Cells: Japan

Regulation of Genome Editing in iPS Cells: Republic of Korea

Comparative Analysis